The association between the apolipoprotein A1/ high density lipoprotein -cholesterol and diabetes in Taiwan - a cross-sectional study

BMC Endocrine Disorders

Volumn 13, Issue , 2013, Pages

  Jian, Zhi Hong ^a   Lung, Chia Chi ^a,b   Ko, Pei Chieh ^a   Sun, Yi Hua ^a   Huang, Jing Yang ^a   Ho, Chien Chang ^c   Ho, Chia Yo ^a   Chiang, Yi Chen ^a   Chen, Chien Jen ^d,e   Liaw, Yung Po ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b Department of Family and Community Medicine   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Apolipoprotein A1; Apolipoprotein B; Diabetes; High density lipoprotein cholesterol; Low density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATININE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; RISK ASSESSMENT; SEX DIFFERENCE; TAIWAN; URIC ACID BLOOD LEVEL;

EID: 84885016219     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-13-42     Document Type: Article

References (43)

1. Chang CH, Shau WY, Jiang YD, Li HY, Chang TJ, Sheu WH, Kwok CF, Ho LT, Chuang LM. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study. Diabet Med 2010, 27(6):636-643. 10.1111/j.1464-5491.2010.03007.x, 20546280.
2. AMERICAN DIABETES ASSOCIATION Standards of medical care for patients with diabetes mellitus. Diabetes care 2003, 26(Suppl 1):S33-S50. AMERICAN DIABETES ASSOCIATION.
3. Luijks H, Schermer T, Bor H, Van Weel C, Lagro-Janssen T, Biermans M, De Grauw W. Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study. BMC Med 2012, 10:128. 10.1186/1741-7015-10-128, 3523042, 23106808.
4. Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med 2011, 9:103. 10.1186/1741-7015-9-103, 3180398, 21902820.
5. Gotto AM. Apolipoproteins and metabolism in atherosclerosis. Trans Am Clin Climatol Assoc 1990, 101:46-57. discussion 57-48, 2376482, 2486446.
6. Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010, 142(1):72-79. 10.1016/j.ijcard.2008.12.066, 19171400.
7. Seo MH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY. Association of lipid and lipoprotein profiles with future development of type 2 diabetes in nondiabetic Korean subjects: a 4-year retrospective, longitudinal study. J Clin Endocrinol Metab 2011, 96(12):E2050-E2054. 10.1210/jc.2011-1857, 21994961.
8. Bardini G, Dicembrini I, Rotella CM, Giannini S. Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance. Acta diabetol 2013, 50:277-281. 10.1007/s00592-011-0339-0, 21997326.
9. Sung KC, Hwang ST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis 2005, 180(1):161-169. 10.1016/j.atherosclerosis.2004.11.009, 15823289.
10. Ying X, Qian Y, Jiang Y, Jiang Z, Song Z, Zhao C. Association of the apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein cholesterol with insulin resistance in a Chinese population with abdominal obesity. Acta diabetol 2012, 49(6):465-472. 10.1007/s00592-012-0419-9, 22965469.
11. Shih YT HY, Chang HY, Liu JP, Lin HS, Chang MC. The design, contents, operation and the characteristics of the respondents of the 2001 National Health Interview Survey in Taiwan. Taiwan J Public Health 2004, 22:419-430.
12. Wen CP, Levy DT, Cheng TY, Hsu CC, Tsai SP. Smoking behaviour in Taiwan, 2001. Tob Control 2005, 14(Suppl 1):i51-55. 1766183, 15923450.
13. Su TC, Bai CH, Chang HY, You SL, Chien KL, Chen MF, Chen HJ, Pan WH, Tseng CH, Cheng SH, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens 2008, 26(3):600-606. 10.1097/HJH.0b013e3282f3b352, 18300873.
14. World Health Organization Physical status: the use and interpretation of anthropometry 1995, Geneva: WHO, World Health Organization.
15. American Diabetes Association Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes care 2010, 33(Suppl 1):S3. 2797388, 20042773, American Diabetes Association.
16. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996, 45(Suppl 3):S27-30.
17. Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, Hegele RA, Zinman B, Hanley AJ. Utility of non-high-density lipoprotein cholesterol in assessing incident type 2 diabetes risk. Diabetes Obes Metab 2012, 14(9):821-825. 10.1111/j.1463-1326.2012.01607.x, 22510237.
18. Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, Hegele RA, Zinman B, Hanley AJ. Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem 2010, 56(4):666-670. 10.1373/clinchem.2009.136994, 20110448.
19. Belfki H, Ben Ali S, Bougatef S, Ben Ahmed D, Haddad N, Jmal A, Abdennebi M, Ben Romdhane H. The Apolipoprotein B/Apolipoprotein A 1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population. Exp Mol Pathol 2011, 91(2):622-625. 10.1016/j.yexmp.2011.06.007, 21801720.
20. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5(5):339-349. 10.1097/00041433-199410000-00005, 7858908.
21. Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001, 86(3):965-971. 10.1210/jc.86.3.965, 11238470.
22. Caixas A, Ordonez-Llanos J, De Leiva A, Payes A, Homs R, Perez A. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 1997, 46(7):1207-1213. 10.2337/diab.46.7.1207, 9200657.
23. Mykkanen L, Kuusisto J, Haffner SM, Laakso M, Austin MA. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol 1999, 19(11):2742-2748. 10.1161/01.ATV.19.11.2742, 10559020.
24. Abate N, Vega GL, Garg A, Grundy SM. Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. Atherosclerosis 1995, 118(1):111-122. 10.1016/0021-9150(95)05597-P, 8579621.
25. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101(9):975-980. 10.1161/01.CIR.101.9.975, 10704163.
26. Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arterioscler Thromb Vasc Biol 1997, 17(1):64-71. 10.1161/01.ATV.17.1.64, 9012639.
27. Al-Bahrani AI, Bakhiet CS, Bayoumi RA, Al-Yahyaee SA. A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. Diabetes Res Clin Pract 2005, 69(1):44-51. 10.1016/j.diabres.2004.09.011, 15904989.
28. Wagner AM, Jorba O, Rigla M, Alonso E, Ordonez-Llanos J, Perez A. LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol 2002, 39(4):215-220. 10.1007/s005920200037, 12486496.
29. Onat A, Can G, Cicek G, Ayhan E, Dogan Y. Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: population-based cohort study. Clin Biochem 2010, 43(18):1381-1386. 10.1016/j.clinbiochem.2010.08.027, 20816677.
30. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995, 36(2):211-228.
31. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977, 1(8019):965-968.
32. Koropatnick TA, Kimbell J, Chen R, Grove JS, Donlon TA, Masaki KH, Rodriguez BL, Willcox BJ, Yano K, Curb JD. A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-american men. J Gerontol A Biol Sci Med Sci 2008, 63(11):1235-1240. 10.1093/gerona/63.11.1235, 19038839.
33. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis 1984, 4(2):79-83. 10.1161/01.ATV.4.2.79, 6422918.
34. Toth PP, Davidson MH. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol 2010, 4(5):359-364. 10.1016/j.jacl.2010.08.002, 21122679.
35. Nobecourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010, 30(4):766-772. 10.1161/ATVBAHA.109.201715, 3038672, 20110571.
36. Park KH, Shin DG, Kim JR, Hong JH, Cho KH. The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int J Mol Med 2010, 25(1):129-136.
37. Schreier LE, Berg GA, Basilio FM, Lopez GI, Etkin AE, Wikinski RL. Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 1999, 47(4):681-690.
38. Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, et al. Relation of central adiposity and body mass index to the development of diabetes in the diabetes prevention program. Am J Clin Nutr 2008, 87(5):1212-1218. 2517222, 18469241.
39. Chien LY, Liou YM, Chen JJ. Association between indices of obesity and fasting hyperglycemia in Taiwan. Int J Obes Relat Metab Disord 2004, 28(5):690-696. 10.1038/sj.ijo.0802619, 15024398.
40. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, De Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012, 308(11):1150-1159. 10.1001/2012.jama.11132, 3556508, 22990274.
41. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001, 161(13):1581-1586. 10.1001/archinte.161.13.1581, 11434789.
42. Cheng CH, Ho CC, Yang CF, Huang YC, Lai CH, Liaw YP. Waist-to-hip ratio is a better anthropometric index than body mass index for predicting the risk of type 2 diabetes in Taiwanese population. Nutr Res 2010, 30(9):585-593. 10.1016/j.nutres.2010.08.007, 20934599.
43. Chen CC, Wang WS, Chang HY, Liu JS, Chen YJ. Heterogeneity of body mass index, waist circumference, and waist-to-hip ratio in predicting obesity-related metabolic disorders for Taiwanese aged 35-64 y. Clin Nutr 2009, 28(5):543-548. 10.1016/j.clnu.2009.04.017, 19473734.